This category will be the broadest, including articles describing new therapies for mesothelioma cancer, comparing various types of therapies and discussing the outcomes following therapy. The most important aspects of the studies which will be highlighted in the commentary shall be: the type of patients analyzed, the form of therapy used and the outcome pursued by the investigators.
Need synopsis. - Expert Rev Respir Med. 2010 Jun;4(3):363-72.
Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion.
Recent clinical trials report encouraging results in selected patients with peritoneal mesothelioma (PM) treated with cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). - Ann Surg Oncol. 2007 Feb;14(2):500-8. Epub 2005 Apr 14.
Current imaging modalities fail to define precisely the extent of disease in MPM and are inaccurate in selecting patients for treatment. - Lung Cancer. 2005 Jul;49 Suppl 1:S27-32. Epub 2005 Apr 14.
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura - a single-institution experience with 189 patients.
A study to determine the factors influencing the response to palliative radiotherapy 9RT) in malignant mesothelioma of the pleura (MM). - Int J Radiat Oncol Biol Phys 1999 Feb 1;43(3):511-6
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
The authors conducted a Phase II trial in which two drugs (etoposide and 5-fluorouracil) were added to the Cancer and Leukemia Group B cisplatin-mitomycin regimen in an effort to define a more effective chemotherapy. - Cancer 1999 Apr 15;85(8):1740-9
This paper reviews the available literature on the systemic drug therapy of MPM. - Monaldi Arch Chest Dis 1998 Apr;53(2):236-40
Management of Mesothelioma By Neoadjuvant Chemotherapy, Followed by Resection and Radiation-A New Approach
A case presentation performed during the Grand Rounds at the Froedtert Hospital on the Management of Mesothelioma discusses the neoadjuvant chemotherapy approach followed by resection and radiation.
Cisplatin is a chemotherapy drug that was approved by the Federal Drug Administration (FDA) in 1978 and is used to treat patients suffering from malignant pleural mesothelioma.
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with malignant pleural mesothelioma: Outcomes of an expanded access program.
An expanded access program (EAP) provided patient access to pemetrexed prior to its commercial availability. - Lung Cancer. 2007 Feb;55(2):187-94
The current review will cover the dramatic improvements in the treatment of this rare disease that have been recently achieved, as well as the promise that new, molecular-targeted therapies, such as bortezomid, mTOR inhibitors, and Met inhibitors, seem to offer for the next few years. - Semin Oncol. 2005 Jun;32(3):336-50
Pemetrexed is a novel antifolate that inhibits several folate-dependent enzymes in addition to thymidylate synthase. Such a drug may have theoretical advantages over fluoropyrimidines and specifically acting antifolates. - Semin Oncol 2002 Apr;29(2 Suppl 5):54-61
Alimta®, a new type of cancer treatment being developed by Eli Lilly, is the first treatment to significantly improve mesothelioma prognosis and ameliorate the symptoms of the disease. - Financial Times 2002 May
Recombinant human interferon gamma (r-hu-IFNgamma) exerts both antitumoral activity in the early stages of human malignant mesothelioma and a cytostatic effect in human mesothelioma (HM) cell lines in vitro. - Oncogene 2001 Mar 1;20(9):1085-93
The CALGB conducted a phase II multicenter trial to evaluate the activity of gemcitabine in malignant mesothelioma (CALGB protocol 9530). - Lung Cancer 2000 Feb-Mar 31(2-3):311-7
Researchers at the Newcastle Freeman Hospital have seen rapid improvements in the symptoms of mesothelioma sufferers taking the breakthrough new drug, Alimta®.- Scotsman 2000 Nov 7;6
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. -Cancer 1999 Jun 15;85(12):2577-82
Researchers at the Veterans Affairs Medical Center and the Department of Medicine at the University of Minnesota may have discovered an effective treatment for mesothelioma using a common cholesterol reducing drug.
Dr. Roman Perez-Soler, Associate Director for Clinical Oncology and Translational Research at the NYU Medical Center's Kaplan Comprehensive Cancer and Research Institute, discusses a promising new therapeutic option for patients with malignant pleural mesothelioma.
Mesothelioma may be particularly well suited for gene therapy treatment owing to its accessibility, allowing both intrapleural and intratumoral gene delivery. - Cancer Gene Ther. 2006 Oct;13(10):897-904. Epub 2006 Jan 27.
As the incidence of this disease has yet to peak, there is a pressing need for new therapeutic approaches. One such approach is gene therapy. - Expert Opin Biol Ther. 2005 Aug;5(8):1039-49.
Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
Several clinical studies have demonstrated objective antitumoral responses to intrapleural interleukin-2 (IL-2) administration in the treatment of malignant pleurisy. - Cancer 1998 Nov 15;83(10):2099-104
This article further explains what mesothelioma is, and mentions gene therapy as a method by which to cure it. Included is contact information for Dr. Joseph A. Treat conducting gene therapy research at the University of Pennsylvania Department of Medicine.
This article discusses the theory behind genes that would attack harmful cancer cells while leaving normal healthy cells alone.
Please see the latest gene therapy treatment study headed by Dr. Paul Schwarzenberger from the LSU Medical Center and Stanley S. Scott Cancer Center.
Investigators at the University of Pennsylvania Cancer Center have been awarded a Program Project grant from the National Cancer Institute that will help fund a novel gene therapy trial to treat patients with mesothelioma, a cancer frequently linked to asbestos exposure.
Photodynamic therapy is one of the most promising new fields of medicine for the treatment of diseases and disorders of tissues. It is safe and non-invasive. Explanations of the procedure and a scientific study are provided here.
The National Cancer Institute provides an easy-to-understand discussion of the development of PDT and its pros and cons.
The LumaCare site provides an abstract and details of a recent study entitled "Photodynamic Therapy of Malignant Mesothelioma of Pleura". The study was conducted at the Norwegian Radium Hospital.
Intralesional infusion of cytokines is feasible but can be associated with systemic toxicity and has considerable technical problems. It produces a localized immune reaction with tumor regression in a minority of patients. - J Immunother 1998 Sep;21(5):389-98
Need synopsis. - Ann Thorac Surg. 2009 Sep;88(3):870-5; discussion 876.
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma
Need synopsis. - J Clin Oncol. 2009 Jun 20;27(18):3007-13. Epub 2009 Apr 13.
Even though followed by a prolonged survival in highly selected patients, the promising results of Sugarbaker's trimodality treatment for malignant pleural mesothelioma (MPM) are debated and not yet uniformly replicated. - J Cardiovasc Surg (Torino). 2006 Oct;47(5):595-601
We reviewed our experience with trimodality management of malignant pleural mesothelioma (MPM). - Eur J Cardiothorac Surg. 2001 Mar;19(3):346-50.
The objective of the study was presentation of the use of pleuropneumonectomy in a multimodality treatment setting and the results. - Chest 1999 Dec;116(3 Suppl):450S-454S
Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.
This study was planned to investigate the feasibility, safety, and pharmacokinetics of a multimodality therapy including an operation, pleural space perfusion (60 minutes) with cisplatin (100 mg/m2), hyperthermia (41.5 degrees C), and postoperative radiotherapy (55 Gy to chest wall incisions). - J Thorac Cardiovasc 1999 Apr;117(4):759-65
David Sugarbaker, M.D., Dana-Farber Cancer Institute
Dr. Lary A. Robinson, M.D., Director, Division of Cardiovascular and Thoracic Surgery